Jay Moyes Sells 22,000 Shares of PBYI in Planned Transaction
Jay Moyes offloaded 22,000 shares of PBYI on June 12, 2026, in a planned sale at $7.22 per share.
Key Points
- Jay Moyes sold 22,000 shares of PBYI for $158,840 on June 12, 2026, in a planned transaction.
- PBYI shares traded at $7.33, with a 52-week range between $0 and an unspecified high.
- Other funds like BlackRock reduced their PBYI holdings, while American Century increased theirs by 266,209 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jay Moyes, a notable insider at PBYI, sold 22,000 shares on June 12, 2026, as part of a planned transaction. The shares were sold at an average price of $7.22, totaling $158,840. This sale was executed under a pre-arranged trading plan.
Insider Buying and Selling at Puma Biotechnology, Inc.
Several insiders were active in June 2026. On June 12, Dorval Allison sold 11,610 shares, Brian Stuglik sold 8,100 shares, Adrian Senderowicz sold 27,000 shares, and Troy Edward Wilson sold 10,800 shares, all at $7.20 each, as part of planned transactions. Interestingly, Jay Moyes also bought 27,000 shares on June 11, suggesting a strategic shift in holdings.
Other Institutional Activity in PBYI
Institutional investors have been busy with PBYI shares. Acorn Capital Advisors maintained its position with 4,131,299 shares valued at about $26.4 million. BlackRock, Inc. trimmed its stake by 43,636 shares, ending with 3,598,952 shares worth approximately $23 million. Acadian Asset Management increased its holdings by 16,936 shares, totaling 2,041,759 shares valued at $13 million. Renaissance Technologies reduced its position by 181,400 shares, while American Century Companies boosted its holdings by 266,209 shares, bringing its total to 1,916,346 shares, valued around $12.2 million.
Puma Biotechnology, Inc. Stock Down 19.1%
PBYI shares recently traded at $7.33. The stock has experienced a 52-week low of $0, while the high remains unspecified. Investors are keeping a close watch on its performance, especially with recent insider and institutional activities.
Analysts Set New Price Targets
HC Wainwright & Co. has reiterated its 'buy' rating on PBYI multiple times, with a price target of $7 as of February 28, 2025. TD Cowen maintained a 'hold' rating with a $4 target, while Barclays held a 'sell' rating with a $2 target. The consensus among analysts is mixed, with a variety of ratings reflecting differing views on the stock's potential.
Bottom Line
Jay Moyes' recent sale of PBYI shares, along with other insider activities, highlights the dynamic changes within the company. Investors closely monitor these insider moves for potential insights, though it's important to remember that such transactions can be planned and not necessarily indicative of future performance. Institutional activity also suggests varied confidence levels among major shareholders.
Get Puma Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PBYI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.